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Previous studies have revealed a loss of enkephalin immunoreactivity in the terminals of striatal neurons projecting 
to the external globus pallidus in patients with early grades of Huntington’s disease (HD). To asess the status of the 
petikarya of striatal enkephalinergic neurons, we performed in situ hybridization histochemistry with a radiolabeled 
RNA probe complementary to preproenkephalin messenger RNA. We studied postmortem brain tissue of 6 patients 
with symptomatic HD, 7 control subjects, and 2 presymptomatic carriers of the HD allele. There was a significant 
reduction in the areal density of striatal neurons expressing preproenkephalin messenger R N A  in the patients with 
symptomatic HD, but the level of labeling in the remaining cells was not altered compared with the control subjects. 
In the specimens from presymptomatir individuals, there was no reduction of areal density of preproenkephalin 
messenger RNA-containing neurons in the striatum, despite the fact that loss of enkephalin immunoreactivity in the 
external globus pallidus had been previously demonstrated in the same brains. The results correlate with the previous 
demonstration of depleted enkephalin immunoreactive terminals in the external globus pallidus in patients with 
symptomatic HD. They also suggest that the early loss of enkephalin immunoreacTivity observed in the external globus 
pallidus of presymptomatic carriers of the HD allele is not related to a generalized death of striatal enkephalinergic 
neurons early in the course of the disease. 
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Striatal atrophy, especially of the caudate nucleus, is 
the histological signature of Huntington’s disease 
(HD). Within the striatum, however, there is differen- 
tial loss of subpopulations of neurons. Striatal neurons 
containing the neuropeptides somatostatin and neuro- 
peptide Y and the enzyme NADPH-diaphorase, ap- 
pear relatively spared in patients with HD [I,  2). The 
perikarya of striatal cholinergic interneurons also a p  
pear spared despite an impressive loss of striatal cho- 
line acetyltransferase levels 13-51. These striatal in- 
terneuron pools represent only a small fraction of the 
neurons within the striatum. The great majority of stri- 
atal neurons are projection neurons and these striatal 
projection neurons are subdivided into different popu- 
lations on the basis of their anatomical connectivity and 
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neuropeptide content [6-11). Striatal neurons pro- 
jecting to the external globus pallidus (GPe) contain 
enkephalin (ENK), whereas those striatal neurons 
projecting to the internal globus palhdus (GPi) contain 
mostly tachykinins (SP: substance P and K) 112, 131. 
Immunohistochernical studies suggest that striatal 
projection neurons are differentially affectecl in the 
course of HD. We have found a decrease in ENK 
irnmunoreactivity in the GPe and of SP immunoreac- 
tivity in the substantia niga pars reticulata in patients 
with early grades of HD 114). Remarkably, this was 
also observed in probable presyrnptomatic carriers of 
the HD allele 1151. In contrast, SP immunoreactivity 
in the GPi is preserved until relatively late in the 
course of the disease, suggesting that striato-GPi neu- 
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rons are relatively spared in patients with early grades 
of HD (1141; for different results see 1163). 
Perikarya of striatal neurons are difficult to visualize 
with immunohistochemistry without intracerebral col- 
chicine treatment, a technique not applicable to hu- 
mans .  To test the hypothesis that the  perikarya of 
striato-GPe projection neurons are affected early in 
the course of HD, we used in situ hybridization histo- 
chemistry with an RNA probe for preproenkephalin 
messenger RNA (PPE mRNA) to determine if the 
perikarya of striatal ENK-containing neurons were de- 
pleted in brains from patients with early grades of HD. 
Material and Methods 
Sn bjectf 
We studied specimens from 6 patients with pathologically 
verified HD (grades 2-4), 7 control subjects, and 2 asymp- 
tomatic individuals who have been shown with very high 
probability, by linkage analysis, to be carriers of the HD 
allele. All patients were pathologically graded according to 
the criteria of Vonsattel and colleagues [17]. There was one 
grade 4, two grade 3, and three grade 2 HD specimens. The 
presymptomatic HD d e l e  carriers had normal neuropatho- 
logical examinations. In particular, they did not show any 
striatal atrophy. Their HD allele status has been established 
by resrriction fragment length polymorphism analysis with a 
degree of confidence of 95% for Patient 1 [is] and 97% for 
Patient 2 (R. Albin, unpublished data). 
Brains were obtained at autopsy, and one hemisphere was 
either frozen whole and stored at - 70'C before subsequent 
sectioning or sectioned into I-cm slabs in a coronal plane, 
and the slabs frozen in crushed dry ice before storage at 
- 70°C. The average postmortem delay for HD specimens 
(excluding the presymptomatic carriers) was 16 hours (range, 
6-24 hours), the average age of patients with HD was 58 
years (range, 12-87 years). For control subjects, the equiva- 
lent numbers were 17 hours (range, 11-23 hours) for post- 
mortem delay and 50 years (range, 23-81 years) for age. The 
average postmortem delay of the presymptomatic specimens 
was 25 hours, and the average age was 30 years. The number 
of years of storage of frozen specimens was 3.3 years for 
tissue from patients with HD, 2.4 years for control subjects, 
and 3.5 years for presymptomatic carriers. Some of the pa- 
tients with HD were receiving neuroleptic medication. Sev- 
eral of the specimens, including both presymptomatic HD 
allele carriers, one of the grade 2 specimens, one of the grade 
3 specimens, and the grade 4 specimen had been previously 
studied with immunohistochemistry to examine the density 
of ENK immunoreactivity in the GPe E14, 151. 
In Situ Hybridization Histochemistry 
PREPARATION OF THE TISSUE. Blocks containing either 
head of the caudate nucleus (all control subjects, all patients 
with HD, and 1 presymptomatic HD carrier) or putamen at 
the level of the pallidum (1 presymptomatic carrier) were 
equilibrated at - 20°C in a Reichert cryostat. Twelve-micron 
sections were cut on the cryostat and rapidly thaw-mounted 
onto gelatin-coated slides (see {IS]). After mounting the sec- 
tions, the slides were stored at - 70°C until the time of assay. 
SYNTHESIS OF THE RADIOLABELED RNA PROBES. The radio- 
labeled complementary RNA (cRNA) probes were tran- 
scribed in vitro from a complementary DNA (cDNA) clone 
for PPE generously given by Dr S. Sabol of the National 
Institute of Mental Health 1191. The 935 base pairs cDNAs 
inserted into the transcription vector PSP64 and PSP65 (Pro- 
mega Corp, Madison, WI) were linearized according to stan- 
dard protocols [20] and used to transcribe antisense and 
sense cRNA probes, respectively. The specificity of the 
cDNA has been assessed previously by Northern analysis 
1191. Similar cRNA probes have given specific hybridization 
signal in in situ hybridization experiments in the rat [21]. 
Transcription was performed in the presence of 2.5 pM of 
35S-UTP (1,000 Ci/mmoi, New England Nuclear, Wihing- 
ton, DE) and 10 pm of unlabeled UTP with ATP, CTP, and 
GTP in excess as described previously {l8]. 
IN SITU HYBRIDIZATION AND RADIOAUTOGRAPHY. All SOlU- 
tions and buffers used were prepared with distilled water 
treated with diethylpyrocarbonate to inhibit RNase activity 
(DEPC; Sigma Chemical, St Louis, MO) and autoclaved. The 
brain sections were quickly dried at room temperature under 
an air flow and fixed by immersion into a solution of 3% 
paraformaldehyde in phosphate buffer containing DEPC 
0.0296. In situ hybridization histochemistry was performed 
as described previously { 18, 22). Briefly, sections were ace- 
tylated, dehydrated, and incubated with 2.5 to 3 ng (in a 
volume of 20 1.) of radiolabeled PPE cRNA (specific activity, 
4 x lo5 cpm/ng) for 2 10 minutes in a convection oven at a 
temperature of 50°C. Posthybridization washes were in 2 X 
standard saline citrate (SSC) containing 50% formamide at 
52°C for 5 and 20 minutes, in RNase A (100 p g / d ;  
Sigma) for 30 minutes at 37"C, and in 2 x SSC containing 
50% formamide for 5 minutes. Sections were kept overnight 
under mild agitation in 2 x SSC containing 0.05% Triton 
X-100 at room temperature, dehydrated in ethanol, delipi- 
dated in xylene, air dried, coated with Kodak NTB3 emul- 
sion diluted 1 : 1 with 300 mM ammonium acetate, air dried, 
and stored in light-tight boxes in the presence of desiccant. 
After 21 days of exposure, the sections were developed in 
Kodak D-19 for 3.5 minutes at 14°C. The sections were 
lightly counterstained with hematoxylin and eosin and 
mounted with Eukitt mounting media (Calibrated Instru- 
ments, Ardsley, NY). Control sections were hybridized in 
parallel with a sense radiolabeled RNA probe (identical to 
the PPE mRNA) under the same conditions. 
QUANTIFICATION OF THE LABELING. Two sections from 
each brain, processed in the same experiment and exposed 
for the same amount of time, were chosen for quantification 
in this study. The number of labeled cells and the intensity 
of labeling were measured by an investigator blind to the 
origin of the specimens. Two methods were used to deter- 
mine the areal density of cells expressing PPE mRNA in the 
striatum. First, all labeled cells present in each section were 
counted by scanning the section with a 10 X objective under 
dark-field illumination; second, the section was visukzed on 
a monitor with the help of a video camera (Morphon system; 
see below). A computer-generated grid corresponding to 
0.026 mm2 of the section was superimposed on each field 
and all the labeled cells in the grid were counted. This was 
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done in a set of six adjacent frames (total surface area, 0.16 
mm2) in four different, arbitrarily chosen areas of each sec- 
tion (two sections per brain). The mean areal densities of 
labeled cells were similar in the eight sets of six frames mea- 
sured in each brain. The mean areal densities of PPE-labeled 
cells obtained with each method were calculated for each 
brain and expressed as the number of labeled cells per milli- 
meters squared. Results from the two methods were in excel- 
lent agreement, and numerical values obtained with the sec- 
ond method are reported here. 
The intensity of labeling over cells was quantified by mea- 
suring the surface area occupied by silver grains over samples 
of labeled cells in the striatum. To collect an unbiased sample 
of cells, the level of labeling over all labeled cells (determined 
as cells covered by 10 or more pixels per cell) present within 
twelve to twenty 0.026-mm2 arbitrarily chosen frames was 
measured, so that a total of 100 cells was measured in each 
section, except for the one HD grade 4, in which a total of 34 
cells was measured. This was accomplished with a Morphon 
image-analysis system (Philadelphia, PA) 1231. The analog 
video signal was converted to a digital image of 5 12 x 480 
pixels. The tissue sections were observed under bright-field 
illumination with a 40 x objective. Threshold illumination 
was adjusted to distinguish silver grains from background 
staining. For each cell, the area of grain occupancy was mea- 
sured and expressed as a number of pixels. Under these con- 
ditions, there is a linear correlation between the number of 
pixels and the number of silver grains counted visually [23}. 
The average number of pixels per cell was calculated for 
each brain. Results obtained in patients with HD and control 
subjects were compared using a nonparametric Mann- 
Whitney rank sum test f241. 
Results 
Density of PPE mRNA Neurons in the Striaturn 
Striatal neurons labeled for PPE mRNA were clearly 
visible in specimens from control subjects, patients 
with HD grades 2 through 4,  and presymptomatic car- 
riers (Figs 1A-C, 2A-D). No labeling was present in 
control sections exposed to the sense probe (Fig 1D). 
The average areal density of striatal PPE mRNA- 
containing neurons was lower in clinically diagnosed 
HD specimens than in control subjects (see Figs lC, 
3). The magnitude of the decrease in grades 2 and 3, 
however, was offset by the existence of a significant 
shrinkage in these HD specimens. The grade 4 speci- 
men had very few PPE mRNA-containing striatal neu- 
rons at a grade when most striatal neurons have degen- 
erated. 
In specimens from the two presymptomatic carriers, 
the density of striatal PPE mRNA-containing neurons 
was within the range of control subjects (see Fig 3), 
even though previous immunohistochemical studies of 
the same brains have shown substantial reduction of 
ENK-immunoreactive terminals within the GPe. A rel- 
ative dissociation of in situ hybridization and immuno- 
histochemical results also exists for one of grade 2 and 
one grade 3 specimens. In these brains, we have pre- 
viously observed near total depletion of GPe ENK- 
immunoreactive suiatal terminals, whereas the present 
in situ results indicate the presence of a sizable num- 
ber of PPE mRNA-containing striatal neurons (103.1 
and 94.6 PPE mRNA-expressing cells per millimeter 
squared, respectively). 
Density of Labeling of PPE 
mRNA-containing Neurons 
Including the grade 4 brain, the average level of label- 
ing per cell was very similar for all specimens examined 
(see Figs 2, 4). Thus, no statistical difference was found 
between level of labeling in brains from control sub- 
jects, presymptomatic carriers, or patients with grades 
2 through 4 HD. No correlation was found between 
level of labeling of individual cells and postmortem 
delay or age of the patients. It should be noted, how- 
ever, that the autoradiographic conditions (exposure 
time) were chosen to ensure visualization of the major- 
ity of striatal cells expressing PPE mRNA, resulting in 
very dense cellular labeling (see Fig 2). Quanthcation 
of individual labeling is not optimal under these condi- 
tions [23}. Subtle differences in the level of labeling 
may therefore have gone undetected. The results, how- 
ever, clearly suggest that high level of expression of 
PPE mRNA is still present in remaining striatal neu- 
rons of patients with grades 0 through 4 HD. 
Discussion 
Our in situ hybridization data confirm the loss of stri- 
atal enkephalinergic neurons documented previously 
with immunohistochemical techniques in patients with 
grades 2 through 4 HD [14, 251. The present in situ 
hybridization results probably underestimate the de- 
gree of enkephalinergic neuron depletion because we 
measured the areal density of PPE mRNA-containing 
striatal neurons, which will be elevated in higher grade 
of HD due to striatal atrophy. With this in mind, there 
is a correlation between the degree of striatal neuro- 
k Fig I .  (A-C) Dark-field photomicrographs of sections from postmortem human brain processed for in  situ hybridization his- 
tochemistry with a 35S-radiokabeled RNA probe complementary 
to preproenkephalin mt?csenger RNA. (A) Section from a control 
brain. Note the high n u m b  of densely labeled cells (examples at 
arrows) identzj5ed by clusters of silver grains (white dots). (B) 
Section from a presymptomatic carrier of Huntington's disease 
(HD) allele (Patient 2). Note that the areal density of labeled 
cells (one at arrow) is similar t o  that of the control subject (A). 
(C) Section from a patient with grad 3 HD.  Labeled cells are 
much less numerous, but still intensely labeled (example at ar- 
row). (0) Dark-field photomicrograph of a section from a con- 
trol brain, serially adjacent to that illustrated in A, hybridized 
with a sense (control) probe. Note the absence of specific label- 
ing. Scale bar = 100 pm. 
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Fig 2. Bright-field photomicrographs of neurons expressing pre- 
proenkephalin messenger RNA in humun striatum. Sections 
were processed as for Figure I. Labeled cells (arrows) are charac- 
terized by the presence of dense clusters of silver grains in the 
overlaying emulsion. Note the lmu autoradiographic background 
and the presence of unlabeled glial cells (some at arrowheads). 
(A) Section from a control subject, also illustrated in Figure IA. 
(B) Section from presymptomatic Patient 2, also illustrated in 
Figure IB.  (C) Section from a patient with grade 3 Hunting- 
toni- disease (HD). (D) Section from a patient with grad. 3 
HD also illustrated in Figure I C. Scale bar = 10 WZ. 
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Fig 3. Areal density of preproenkephaiin mesrenRer RIVA-ex- 
pressing ceih in human striaturn. Sections hate bren ~ W C K J J K ~  
and duta quantrfied as indicated in Subjects und Methods. 
Data for C and HD are n ~ m  + SEM of acerage taiues oh- 
tained in each individual. C = control subjects f n  = 7); l i D  
= patients with symptomatic Huntington disease. grades 2-4 
(n = 6): PSI and PS2 = acerage calues obtained in presymp- 
tomatic carriers of HD allele (Patients I and 2, respect ire^^). 
*p - 0 . 0 1  I ueith a Mann-Whitney U test. 
nal loss as determined by pathological grade and the 
degree of PPE mRNA-containing neuron depletion, 
with the grade 2 specimen having a higher density 
of PPE mRNA-containing neurons than the grade 
4 specimen. Similarly, the normal density of PPl3 
&‘A-containing neurons observed in presymptom- 
atic carriers of the HD allele parallels the absence of 
major loss of neurons in the striatum. 
The decreased number and density of pcrikarya ex- 
pressing PPE mRNA in the striata of patients with 
symptomatic HD is likely to  explain the decrease in 
ENK immmunoreactivity in GPe of patients with 
grades 2 through 4 HD [Id]. The normal number of 
labeled neurons observed in presymptomatic patients, 
however, sharply contrasts with the results of previous 
immunohistochemical studies, which showed a loss of 
ENK immunoreactivity in the GPe in these presymp- 
tomatic carriers ((151 and R. Albin, unpublished re- 
sults). Because only discrete regions of the striatum 
were examined, our results do  not rule out the exis- 
tence of a selective loss of enkephalinergic neurons in 
some parts of the suiatum that were not contained in 
the samples studied here. This could occur, for exam- 
ple, in the dorsomedial region of the caudate nucleus, 
which shows early signs of cell loss in patients with 
HD, and in which cell loss has been recorded in pa- 
tients with grade 0 HD { l?]. Such localized cell death, 
however, would not be sufficient to account for the 
loss of ENK immunoreactivity observed in the GPe of 
W 
k 
C HD PSI PS2 
Fig 4. Intensity of labeling (pixels per cell) of prepmenkephaiin 
messenger RR;A-expmsing ceih in human striatum. Sections 
u,ere procr.r.red and results quantified as Ascribed i n  sxbjecis 
and Methods. Data for C and H D  are man f SEM of aver- 
age value obtained in each individrdai. C = control subjects In 
= 7): IiD = patients u>*ith sJmptornatic Iluntington’s disease, 
grades 2-4  ( n  = 6); PSI and PS;? = praymptomatic cawiers 
~ j ~ t h e  H D  d e i e  (Patients I and 2 ,  respecticelyl. 
thesc individuals. The areas examined in this study 
(head of caudate nucleus for Patient 2 and middle of 
putamen for Patient 1) correspond to areas shown in 
nonhuman primates to project to the area of GPe 
showing loss of ENK immunoreactivity in these pa- 
tients ( 7 ,  8, 10, l l ,  261. 
Discrepancy between the loss of a marker of nerve 
terminal integrity and survival of perikarya has been 
seen prcviously in both patients with HD and patients 
with Alzheimer’s disease. Biochemical studies demon- 
strating loss of choline acetyltransferase activity led to 
the conclusion that striatal cholinergic interneurons de- 
generate in patients with HD [ 5 ,  27). More recent 
studies with acetylcholinesterase histochemistry and 
immunohistochemistry with antisera directed against 
choline acctyluansferase have shown preservation of 
the perikarya of striatal cholinergic neurons in patients 
with I-ID 13, 4).  Similarly, in patients with Alzheimcr’s 
disease, a severe reduction in neocortical choline ace- 
tyltransferase activity is not always accompanied by loss 
of basal forebrain neurons giving rise to the cholinergic 
afferents of the neocortex 128). 
The dissociation between the present in situ hybrid- 
ization results and immunohistochemistry in the pre- 
symptomatic specimens could be related to a defect in 
the regulation of ENK metabolism. Defects could exist 
in translation, posttranslational modifications, and peri- 
k q a l  processing of the translated protein, or there 
could be enhanced turnover of the find peptide. Other 
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alternatives would be deficient transport of the final 
peptide or its precursors from the perikaryon to the 
axon terminal or degeneration of axon terminals in the 
GPe. There is a previous suggestion of abnormal regu- 
lation of neuropeptide production in patients with HD. 
Beal and co-workers C291 have shown that somato- 
statin levels are increased in early grade HD specimens 
where striatal atrophy is minimal, suggesting that ele- 
vated somatostatin concentration is not due to concen- 
trative effects secondary to atrophy. 
The level of labeling for PPE mRNA per cell was 
not different in HD (grades 0-4) compared with con- 
trol specimen. Even in the one grade 4 brain examined, 
labeling in the rare remaining cells was intense, with 
most of the values within the range of the control sub- 
jects. Several of the patients with HD were treated 
with neuroleptics, and haloperidol treatment in rats in- 
creases PPE mRNA levels in striatum E30, 3 17. Neuro- 
leptic stimulation of PPE mRNA is unlikely to explrun 
our results because, in experimental animals, the stimu- 
latory effects of haloperidol are no longer seen after 4 
weeks of continuous treatment C2 17. Intensely labeled 
cells were found in areas of the striatum in which areal 
density of PPE mRNA-containing cells was markedly 
decreased compared with control subjects, suggesting 
that a population of neurons actively expressing PPE 
mRNA survives in the brain of patients with HD de- 
spite progressive neuronal loss. 
Although our results do not exclude the possibility 
that PPE mRNA is expressed in HD brains by neurons 
that do not normally express this mRNA, the results 
from patients with symptomatic and presymptomatic 
HD are consistent with the conclusion that enkephalin- 
ergic striatal neurons pass through a phase in which 
abnormalities of neurotransmitter metabolism, axonal 
transport, or terminal structure occur before cell death. 
This information may be of value in attempting to un- 
derstand the pathogenesis of cell death in patients with 
HD. These findings also have implications for attempts 
to treat patients with HD. A therapy that interferes 
with the basic mechanism of cell death in patients with 
HD may result in rescue of dysfunctional neurons and 
actually reverse rather than merely halt the progression 
of HD. 
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